Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.
Blood|January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Haematologica|July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
The Journal of Molecular Diagnostics : JMD|October 12, 2025
Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing DataMuneeza Maqsood, John Toubia, Carol Wadham, et al.
Leukemia Research|March 2, 2018
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyDevendra Hiwase, Peter Tan, James D'Rozario, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Blood|September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Leukemia|August 13, 2020
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responsesShady Adnan Awad, Olli Dufva, Aleksandr Ianevski, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.
Blood|January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Haematologica|July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
The Journal of Molecular Diagnostics : JMD|October 12, 2025
Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing DataMuneeza Maqsood, John Toubia, Carol Wadham, et al.
Leukemia Research|March 2, 2018
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyDevendra Hiwase, Peter Tan, James D'Rozario, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Blood|September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Leukemia|August 13, 2020
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responsesShady Adnan Awad, Olli Dufva, Aleksandr Ianevski, et al.
Pageof 14